Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05228210 · ClinicalTrials.gov registry record
Breast Cancer Self-Efficacy Scale for Partners
A clinical trial, sponsored by Indiana University.
- Terminated
- Registry status
- 25
- Enrollment target
NCT05228210: Clinical Trial study, sponsored by Indiana University.
NCT05228210 is a clinical trial that was terminated before completion, run by Indiana University. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05228210 was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- 25 participants
- Enrollment target
Study Summary
The concept of self-efficacy is a major predictor of physical, psychological, social and overall quality of life (QoL) among breast cancer survivors (BCS). Because survivor and partner outcomes are often linked, it is reasonable to hypothesize that self-efficacy is an important predictor of physical, psychological, social and overall QoL in partners as well. However, this hypothesis has yet to be tested, in part because no scale exists to measure cancer-related self-efficacy in partners. Development and psychometric testing of such a scale is a critical first step in developing a theoretical model predicting QoL in this population. Partners of BCS often report lower QoL compared to partners of healthy women, making them an important focus of research. During the award period, the applicant will follow standard instrument development procedures to develop the Breast Cancer Self-Efficacy Scale for Partners (BCSES-P) and test the scale's psychometric properties using a large and diverse sample of partners of breast cancer survivors.
Primary Outcome
7-item scale assessing concerns that the cancer will progress or return, previously tested in samples of breast cancer survivor caregivers/spouses, Cronbach alpha=.91.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2022-03-01 |
Why NCT05228210 stopped before completion
NCT05228210 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT05228210 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05228210 about?
NCT05228210 is a clinical study titled "Breast Cancer Self-Efficacy Scale for Partners". The concept of self-efficacy is a major predictor of physical, psychological, social and overall quality of life (QoL) among breast cancer survivors (BCS). Because survivor and partner outcomes are often linked, it is reasonable to hypothesize that self-efficacy is an important predictor of physical...
What is the current status of trial NCT05228210?
This trial is currently terminated. The enrollment target is 25 participants. The study started on 2019-09-01. Estimated completion is 2022-03-01.
Who is sponsoring clinical trial NCT05228210?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI